Solid Biosciences Inc

자세한 내용은 Solid Biosciences Inc 회사

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

회사 정보

종목 코드 SLDB

회사 이름Solid Biosciences Inc

상장일Jan 26, 2018

CEOMr. Alexander (Bo) Cumbo

직원 수100

유형Ordinary Share

회계 연도 종료Jan 26

주소500 Rutherford Avenue

도시CHARLESTOWN

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02129

전화16173374680

웹사이트https://www.solidbio.com/

종목 코드 SLDB

상장일Jan 26, 2018

CEOMr. Alexander (Bo) Cumbo

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Ilan Ganot

Co-Founder, Director

132.92K

--

Mr. Ian F. Smith, CPA

Executive Chairman of the Board

122.12K

+3.89%

Mr. Alexander (Bo) Cumbo

President, Chief Executive Officer, Director

60.72K

--

Mr. David Tyronne (Ty) Howton, Jr.

Chief Operating Officer, General Counsel, secretary

24.79K

--

Mr. Kevin Tan

Chief Financial Officer, Treasurer

23.95K

+45.26%

Dr. Jessie Hanrahan, Ph.D.

Chief Regulatory Officer

19.28K

+35.45%

Mr. Paul Herzich

Chief Technology Officer

13.23K

+51.52%

Dr. Sukumar Nagendran, M.D.

Independent Director

4.15K

--

Dr. Martin I. Freed, M.D.

Independent Director

3.58K

--

Dr. Clare Kahn, Ph.D.

Independent Director

2.96K

+169.09%

이름

이름/직위

직위

주식 보유

변동

Mr. Ilan Ganot

Co-Founder, Director

132.92K

--

Mr. Ian F. Smith, CPA

Executive Chairman of the Board

122.12K

+3.89%

Mr. Alexander (Bo) Cumbo

President, Chief Executive Officer, Director

60.72K

--

Mr. David Tyronne (Ty) Howton, Jr.

Chief Operating Officer, General Counsel, secretary

24.79K

--

Mr. Kevin Tan

Chief Financial Officer, Treasurer

23.95K

+45.26%

Dr. Jessie Hanrahan, Ph.D.

Chief Regulatory Officer

19.28K

+35.45%

수익 분석

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

데이터 없음

지역별USD

이름

수익

비율

United States

0.00

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

Perceptive Advisors LLC

15.36%

Bain Capital Life Sciences Investors, LLC

10.21%

Invus Public Equities Advisors, LLC

9.57%

Adage Capital Management, L.P.

8.68%

Commodore Capital LP

7.51%

Other

48.67%

주주

비율

Perceptive Advisors LLC

15.36%

Bain Capital Life Sciences Investors, LLC

10.21%

Invus Public Equities Advisors, LLC

9.57%

Adage Capital Management, L.P.

8.68%

Commodore Capital LP

7.51%

Other

48.67%

주주 유형

주주

비율

Investment Advisor

32.52%

Hedge Fund

31.63%

Private Equity

15.36%

Investment Advisor/Hedge Fund

13.19%

Venture Capital

8.97%

Research Firm

0.87%

Individual Investor

0.56%

Bank and Trust

0.04%

Family Office

0.01%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

235

79.94M

103.13%

+26.28M

2025Q1

237

79.86M

103.02%

+25.88M

2024Q4

198

36.85M

67.00%

-4.80M

2024Q3

199

36.30M

93.97%

-4.52M

2024Q2

188

37.99M

98.93%

-1.65M

2024Q1

182

35.35M

93.37%

+4.46M

2023Q4

181

16.93M

83.83%

-1.01M

2023Q3

190

16.39M

81.73%

-2.06M

2023Q2

203

16.54M

84.41%

-1.08M

2023Q1

234

16.00M

82.14%

-1.37M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Perceptive Advisors LLC

11.91M

15.36%

--

Mar 31, 2025

Bain Capital Life Sciences Investors, LLC

7.91M

10.21%

+2.88M

+57.15%

Mar 31, 2025

Invus Public Equities Advisors, LLC

7.42M

9.57%

+3.67M

+97.81%

Mar 31, 2025

Adage Capital Management, L.P.

6.73M

8.68%

+4.98M

+284.96%

Mar 31, 2025

Commodore Capital LP

5.83M

7.51%

--

Mar 31, 2025

RA Capital Management, LP

4.33M

5.59%

+90.74K

+2.14%

Mar 31, 2025

Fidelity Management & Research Company LLC

3.52M

4.54%

+3.47M

+7432.14%

Mar 31, 2025

VR Adviser, LLC

2.48M

3.2%

+2.48M

--

Mar 31, 2025

The Vanguard Group, Inc.

2.46M

3.17%

+1.06M

+75.59%

Mar 31, 2025

Redmile Group, LLC

2.02M

2.6%

+1.40M

+228.19%

Mar 31, 2025

6.710USD

Solid Biosciences Inc

6.710

개요

회사

금융